Treatment of bone disorders with skeletal anabolic drugs

Details Treatment of bone disorders with skeletal anabolic drugs Treatment of bone disorders with skeletal anabolic drugs

2006-03-21

2006-03-21

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S324000

Reexamination Certificate

active

07015195

ABSTRACT:
Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

REFERENCES:
patent: 4656250 (1987-04-01), Morita et al.
patent: 4771124 (1988-09-01), Rosenblatt et al.
patent: 5229489 (1993-07-01), Kanmera et al.
patent: 5589452 (1996-12-01), Krstenansky et al.
patent: 5693616 (1997-12-01), Krstenansky et al.
patent: 5695955 (1997-12-01), Krstenansky et al.
patent: 5798225 (1998-08-01), Krstenansky et al.
patent: 5807823 (1998-09-01), Krstenansky et al.
patent: 5821823 (1998-10-01), Bereza
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 5847086 (1998-12-01), Farb et al.
patent: 5874086 (1999-02-01), Krstenansky et al.
patent: 6051686 (2000-04-01), Krstenansky et al.
patent: 6273598 (2001-08-01), Keck et al.
patent: 4203040 (1993-08-01), None
patent: 293158 (1988-11-01), None
patent: 451867 (1991-10-01), None
patent: 477885 (1992-04-01), None
patent: 561412 (1993-09-01), None
patent: WO 92/00753 (1992-01-01), None
patent: WO 92/10515 (1992-06-01), None
patent: WO 92/11286 (1992-07-01), None
patent: WO 93/06846 (1993-04-01), None
patent: WO 93/20203 (1993-10-01), None
patent: WO 94/01460 (1994-01-01), None
patent: WO 94/02510 (1994-02-01), None
patent: WO 94/03201 (1994-02-01), None
patent: WO 95/02610 (1995-01-01), None
patent: WO 98/05683 (1998-02-01), None
patent: WO 99/12561 (1999-03-01), None
Abou-Samra et al.,Endocrinology, 125: 2594-2599 (1989).
Abou-Samra et al.,Endocrinology, 129: 2547-2554 (1991).
Blind et al.,Clin. Endocrinol., 101: 150-155(1993).
Brown et al.,Biochem., 20:4538-4546 (1981).
Burtis et al.,J. Biol. Chem., 262: 7151-7156 (1987).
BurtisClin. Chem., 38: 2171-2183 (1992).
Carter et al.,Biochem. Biophys. Acta, 538: 290-304 (2001).
Casey et al.,Nucl. Acid Res., 4: 1539 (1977).
Caufield et al.,Endocrinol., 123:2949-2951 (1988).
Caye et al.,J. Clin. Endocrinol., Metab., &: 199-208 (1996).
Chestnut et al.,Osteoporosis IntB (sup pl3): 13 (1998).
Chorev et al.,J. Bone. Min. Res., 4: S270 (1989).
Cohen et al.,J. Biol. Chem., 266:1997-2004 (1991).
Dayhoff et al., 5 Atlas of Protein Sequence and Structure, 345-352. (1978 & Suppl.).
Delmas et al.,N. Engl. J. Med., 337: 1641-1647 (1997).
Dempster et al.,Endocrine Reviews, 14:690-709 (1993).
Dobnig & Turner,Endocrinology, 138:4607-4612 (1997).
Ettinger et al.,JAMA, 282:637-45 (1999).
Finkelstein et al.,N. Engl J. Med., 331: 1618-1623 (1994).
Fitzpatrick et al.,J. Biol. Chem., 244: 3561-3569 (1969).
Fogelman et al., J. Clin. Endocrinol. Metab., 85:1895-1900 (2000).
Frolick et al.,J. Bone Min. Res., 14: 163-72 (1999).
Fujimori et al.,Endocrinology, 130: 29-60 (1992).
Fujimori et al.,Endocrinology, 128: 3032-3039 (1991).
Fukuyama et al.,Endocrinology, 131: 1757-1769 (1992).
Fukayama et al.,Endocrinology, 134: 1851-1858 (1994).
Gamse et al.,J. Bone Min. Res., 12(suppl):S317(1997).
Gundberg, et al., J. Clin. Endocrinol. Metab., 83:3258-3266, (1998).
Henry et al.,J. Clin. Endocrinol. Metab., 82: 900-906 (1997).
Hirano et ai.,J. Bone. Min. Res., 14: 536-545 (1999).
Hock et al.,Endocrinology, 125: 2022-2027 (1989).
Hock et al.,J. Bone. Min. Res., 7 : 65-72 (1992).
Hodsman et al.,J. Clin. Endocrinol. Metab., 82: 620-628 (1997).
Janulis et al.,Endocrinology, 133: 713-719 (1993).
Jouishomme et al.,Endocrinology, 130: 53-60 (1992).
Juppner et al.,J. Biol., Chem., 263: 8557-8560 (1988).
Karaplis A.C.,. Abstract 1052, Annual Meeting of the American Society for Bone and Mineral Research, Sep. 2002, San Antonio, TX .J. Bone Mineral Res., 17(Suppl. 1), S138 (2002).
Lane et al.,J. Clin. Invest., 102: 1627-1633 (1998).
Libeman et al.,N. Engl. J. Med., 333: 1437-1443 (1995).
Lindsay et al.,Lancet, 350: 550-555 (1997).
McClung et al.,N. Engl. J. Med., 344: 333-40 (2001).
Merendino et al.,Science, 231: 388-390 (1986).
Moseley et al.,Proc. Natl. Acad. Sci. USA., 84 5048-5052 (1987).
Munson et al.,Anal. Biochem., 107:220-239 (1980).
Murphy et al., J. Clin. Endocrinol. Metab., 86:1116-25 (2001).
Neer et al.,N. Engl. J. Med., 344: 1434-1441 (2001).
Orloff et al.,J. Biol. Chem., 264: 6097-6103 (1989).
Orloff et al.,J. Bone Min. Res., 6: 279-287 (1991).
Orloff et al.,Endocrinology, 131: 1603-1611 (1992).
Orloff et al.Am. J. Physiol., 262: E599-E607 (1992).
Pepi Trial,JAMA, 276:1389-1396 (1996).
Pines et al.,Endocrinology, 135: 1713-1716 (1994).
Plotkin et al.,J. Clin. Endocrinol. Metab., 83: 2786-2791 (1998).
Reid et al.,N. Engl. J. Med., 346:653-61 (2002).
Roe et al.,Program and Abstracts of the 81st Annual Meeting of the Endocrine Society, San Diego, CA, Jun. 12-15, p. 59 (1999).
Rosen et al.,J. Clin. Endocrinol. Metab., 86: 957-964 (2001).
Schemer,J. Bone&Min. Res., 6: 149-155 (1991).
Shimizu et al.,J. Biol. Chem., 276: 49003-49012 (2001).
Shimizu et al.,Endocrinology, 42: 3068-3074 (2001).
Shimizu et al.,J. Biol. Chem., 275: 21836-21843 (2000).
Sistare et al.,Pharmacopeial Forum. 20: 7509-7520 (1994).
Stewart et al.,N. Engl. J. Med., 303: 1377-1383 (1980).
Stewart et al.,J. Clin. Endo. Metab., 55: 219-227 (1982).
Stewart et al.,Biochem. Biophys. Res. Comm., 146: 672-678 (1987).
Stewart et al.,J. Clin. Invest., 81: 596-600 (1988).
Stewart et al.,J. Bone Min. Res., 15: 1517-1525 (2000).
Strewier et al.,J. Clin. Invest., 80: 1803 (1987).
Vickery et al.,J. Bone Miner. Res., 11: 1943-1951 (1996).
Wu et al.,J. Biol. Chem., 271: 24371-24381 (1996).
Yang et al.,Biochem., 33: 7460-7469 (1994).
Yang et al., In: Bilezikian, Raisz, and Rodan (Eds). Principles of Bone Biology. Academic Press, San Diego CA, pp. 347-376 (1996).
Yasuda et al.,J. Biol. Chem., 264: 7720-7725 (1989).

Affiliated with

Also associated with

Rating

Treatment of bone disorders with skeletal anabolic drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of bone disorders with skeletal anabolic drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bone disorders with skeletal anabolic drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3533715